Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 180

Results For "ASH"

1865 News Found

Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia
Policy | August 09, 2021

Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia

Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease


Sanofi to acquire Translate Bio
Biotech | August 07, 2021

Sanofi to acquire Translate Bio

Advances deployment of mRNA technology across vaccines and therapeutics development


India’s gets its first bio-bank for heart failure research
Drug Approval | August 06, 2021

India’s gets its first bio-bank for heart failure research

Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology


Clarivate  acquires Bioinfogate
Digitisation | August 05, 2021

Clarivate acquires Bioinfogate

Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences


Govt committed to recognise healthcare workers engaged in Covid-19
Policy | August 04, 2021

Govt committed to recognise healthcare workers engaged in Covid-19

Five seats reserved for Wards of COVID warriors in central MBBS admission


Wipro GE Healthcare introduces remote monitoring solution for COVID 19
Healthcare | August 04, 2021

Wipro GE Healthcare introduces remote monitoring solution for COVID 19

Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22